STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases $63,277.60 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 3,620 shares of the business’s stock in a transaction on Thursday, March 27th. The stock was bought at an average cost of $17.48 per share, with a total value of $63,277.60. Following the completion of the purchase, the insider now directly owns 12,424,944 shares in the company, valued at approximately $217,188,021.12. The trade was a 0.03 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was acquired at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The shares were acquired at an average cost of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The shares were bought at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The stock was bought at an average cost of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. acquired 21,155 shares of STAAR Surgical stock. The stock was bought at an average price of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Stock Performance

STAA stock traded up $0.22 during midday trading on Friday, reaching $17.79. 818,576 shares of the company were exchanged, compared to its average volume of 780,698. The company has a market cap of $877.49 million, a price-to-earnings ratio of -43.39 and a beta of 0.66. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68. The stock’s 50-day simple moving average is $19.52 and its 200 day simple moving average is $25.32.

Wall Street Analyst Weigh In

A number of research firms have commented on STAA. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. William Blair cut STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Canaccord Genuity Group cut their price target on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Jefferies Financial Group cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Finally, BTIG Research cut shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, STAAR Surgical currently has a consensus rating of “Hold” and an average price target of $25.29.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Resona Asset Management Co. Ltd. purchased a new stake in STAAR Surgical in the fourth quarter valued at $36,411,000. Vanguard Group Inc. increased its position in shares of STAAR Surgical by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after purchasing an additional 319,441 shares in the last quarter. Yunqi Capital Ltd lifted its holdings in shares of STAAR Surgical by 48.9% in the 4th quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock valued at $18,640,000 after purchasing an additional 252,113 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after purchasing an additional 172,779 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of STAAR Surgical by 25.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock valued at $20,728,000 after purchasing an additional 171,046 shares during the period. 96.70% of the stock is owned by hedge funds and other institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.